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Background
Plasmodium vivax is the main cause of malaria infection
in Asian, Central and South American countries [1]. It
accounts for more than 90% annually of the reported
malaria cases in Iran [2]. Plasmodium vivax resistant to
chloroquine has emerged in some regions of Asia and
resistance or tolerance to primaquine has been demon-
strated in several countries [3,4]. The aim of this study
was to determine the therapeutic efficacy of chloroquine
and primaquine for Plasmodium vivax malaria treatment
in southeast Iran.
Material and methods
A total of randomly selected 270 patients with confirmed
P. vivax infection participated in 28-day in vivo study that
extended for 2 years for detecting relapse infection. Chlor-
oquine and primaquine were administrated during 3 days
and 8 weeks respectively in 2010. The thick and thin film
blood smears were screened for malaria parasites by
microscopy. The nested PCR was applied using the
Plasmodium 18 subunit ribosomal ribonucleic (Ssr RNA)
genes for detecting mixed infections and diagnosis of para-
sites in the samples with low parasite on days monitoring
the drug resistance.
Results
Fever resolved on the first day in all subjects. Micro-
scopy findings showed that P. vivax was cleared in 15%,
50%, 95%, and 100% of patients on days 1, 2, 3 and 4,
respectively. All 270 subjects showed ~120 Bp band in
the nested PCR which was indicative of P. vivax malaria
on the zero days. Six patients (2.2%) had specific
P. vivax band in nested PCR on day 5. No recurrence
was observed on days 7, 14 and 28 in thick blood smear
and nested PCR. Mean (±standard deviation) parasite
clearance time was 2.41 (±0.8) days. Two patients had
P. vivax malaria clinical and parasitological infection fol-
lowing 8 and 12 months after primary P. vivax malaria
infection.
Conclusions
The findings of this study showed susceptibility of
P. vivax to chloroquine in South east Iran. This finding
is compatible with results of neighboring countries
Pakistan and Afghanistan. Nested PCR was a suitable
assay to determine exact malaria parasite clearance time
in our study. The further investigation is being con-
ducted in two reinfection cases by PCR -Single strand
conformational polymorphism method to differentiate
between relapse and new P. vivax infection.
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